Language Function in Patients With Brain Tumors
This study has been completed.
Sponsor:
Memorial Sloan-Kettering Cancer Center
Information provided by:
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00599703
First received: January 11, 2008
Last updated: July 7, 2009
Last verified: July 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to use an imaging method called functional magnetic resonance imaging (fMRI) in patients who have a tumor near an area of the brain that is believed to control language. The fMRI is a new kind of imaging that uses a strong magnetic field to look at functioning brain tissue. This kind of imaging will be used to study the effect of the brain tumor on your speech.
| Condition | Intervention |
|---|---|
|
Brain Cancer CNS Cancer |
Other: fMRI Scan, pre- and post language evaluation |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Reorganization of Language Function in Patients With Brain Tumors |
Resource links provided by NLM:
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
- To identify language organization prior to surgery in patients in whom a tumor invades or is directly adjacent to the expected location of one of the language centers. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To assess language reorganization over time. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
| Enrollment: | 7 |
| Study Start Date: | May 2005 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
neurosurgical patients
|
Other: fMRI Scan, pre- and post language evaluation
All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
MSKCC clinics
Criteria
Inclusion Criteria:
- Patient in whom a tumor invades or is directly adjacent to the expected location of one of the language centers.
- At least 18 years of age
- English as first language
Exclusion Criteria:
- Patients with high grade tumors
- History of significant psychiatric condition (e.g. schizophrenia, obsessive-compulsive disorder, significant dementia),
- History of the following neurological conditions: CVA, demyelinating conditions, cerebral palsy, Alzheimer's disease.
- History of significant claustrophobic reactions.
- Pregnancy
- Standard contraindications to MR examinations (e.g. implanted stimulator)
- Patients, who were treated prior to our first scan, will not be eligible to participate in this study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599703
Locations
| United States, New York | |
| Memorial Sloan Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
| Principal Investigator: | Andrei Holodny, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Andrei Holodny, M.D., Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00599703 History of Changes |
| Other Study ID Numbers: | 05-043 |
| Study First Received: | January 11, 2008 |
| Last Updated: | July 7, 2009 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site |
Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013